drugset

drugset / Trial / NCT00090649

Study Evaluating DVS-233 SR And Venlafaxine ER In Adult Outpatients With Major Depressive Disorder

NCT00090649 ↗

Phase 3 Completed 369 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedParallel-groupDouble-blindTreatment

Summary

To compare the antidepressant efficacy and safety of DVS-233 SR with those of placebo in adult outpatients with MDD.

Timeline

Start: —
Primary completion: 2005-03
Completion: 2005-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Desvenlafaxine	Other / unclassified	—	—

Indications